Abstract
Objectives To investigate the impact of SARS-CoV-2 infection on the antimicrobial resistance (AMR) gene profiles in the upper respiratory tract (URT) and To evaluate variations in AMR gene diversity, abundance, and ESKAPE-associated AMR in URT. By comparing SARS-CoV-2-positive patients to healthy controls.
Methods 95 URT swab samples from SARS-CoV-2-positive (n=48) and RTPCR-negative control participants (n=47) collected from central India. Metagenomic DNA was extracted, and metagenomic sequencing was performed using the Illumina NextSeq550 platform. Sequencing data were analysed using the Chan Zuckerberg ID pipeline for Antimicrobial resistance (AMR) gene detection and taxonomic profiling. Chao1, Shannon and Simpson diversity indices, Bray-Curtis dissimilarity, and Bayesian regression, were used to identify significant differences in AMR gene abundance and microbial associations.
Results The Chao1 index (p=0.01651) of SARS-CoV-2 samples indicated significantly higher AMR gene richness than the controls. Resistance genes, such as mecA, blaOXA-48, and blaNDM-1, showed higher abundance in SARS-CoV-2 samples. These genes were found to be linked to high-priority pathogens like Klebsiella pneumoniae, Escherichia coli, and Staphylococcus aureus. Bayesian regression demonstrated that SARS-CoV-2 infection is a significant factor in elevated AMR gene abundance (β = 1.549, HDI [1.409, 1.691]). Females showed higher AMR levels than males (β = 0.261, HDI [0.167, 0.350]), and the model outputs showed no significant age correlation. Sankey diagrams and heatmaps showed higher AMR gene diversity and abundance in the SARS-CoV-2 group.
Conclusions SARS-CoV-2 infection alters the URT’s AMR gene profile and increases the resistance genes’ abundance and diversity. The results indicate a requirement to enhance AMR surveillance of COVID-19 patients to adapt antimicrobial stewardship strategies and reduce the chances of secondary infections. It is, therefore, essential to carry out more extensive studies to analyze temporal variations and the effects of antibiotic overuse on AMR evolution.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors are thankful to CSIR-NEERI for providing funds under project OLP-57 (March 2023 -April 2024) for conducting this study This manuscript has obtained the approval of the Knowledge Resource Center (KRC) publication committee of CSIR-NEERI (KRC No.: CSIR-NEERI/KRC/2024/NOV/EEPM/1) Date: 14-11-2024
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Ethics Committee for Research on Human Subjects (IEC) of CSIR-NEERI, Nagpur-20, India.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Revisions in data analysis and manuscript text
